List of Excipients in Branded Drug ZOLADEX

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
A-S Medication Solutions	ZOLADEX	goserelin acetate	50090-3466	GLYCOLIC ACID	1969-12-31
A-S Medication Solutions	ZOLADEX	goserelin acetate	50090-3466	LACTIC ACID, DL-	1969-12-31
TerSera Therapeutics LLC	ZOLADEX	goserelin	70720-950	GLYCOLIC ACID	1969-12-31
TerSera Therapeutics LLC	ZOLADEX	goserelin	70720-950	LACTIC ACID, DL-	1969-12-31
TerSera Therapeutics LLC	ZOLADEX	goserelin	70720-951	GLYCOLIC ACID	1969-12-31
TerSera Therapeutics LLC	ZOLADEX	goserelin	70720-951	LACTIC ACID, DL-	1969-12-31

Zoladex Excipient Strategy and Commercial Opportunities

Last updated: August 27, 2026

Zoladex is a long-acting goserelin acetate implant built around a biodegradable lactide-glycolide polymer matrix. Its commercial value comes from controlled release, depot persistence, administration by healthcare professionals, and reduced dosing frequency rather than from the active ingredient alone. The strongest opportunities are complex-generic development, polymer and implant manufacturing, differentiated depot products, supply-chain licensing, and lifecycle extensions that improve insertion, storage, or release performance.

What excipients are used in Zoladex implants?

Zoladex uses a biodegradable lactide-glycolide copolymer as the principal functional excipient. The polymer controls the release of goserelin acetate after subcutaneous implantation. The product is supplied as a solid cylindrical depot implant in a prefilled syringe applicator.

Product	Active ingredient	Dose	Dosing interval	Functional excipient system	Route
Zoladex 3.6 mg	Goserelin acetate equivalent to 3.6 mg goserelin	3.6 mg	Every 28 days	Biodegradable lactide-glycolide copolymer	Subcutaneous implant
Zoladex 10.8 mg	Goserelin acetate equivalent to 10.8 mg goserelin	10.8 mg	Every 12 weeks	Biodegradable lactide-glycolide copolymer	Subcutaneous implant

The FDA labeling identifies the implant matrix as a biodegradable lactide-glycolide copolymer. The polymer gradually hydrolyzes into lactic acid and glycolic acid, which are subsequently metabolized or eliminated through normal physiological pathways.[1,2]

The key excipient is therefore not a conventional tablet filler or solution stabilizer. It is a drug-delivery material that determines:

• Initial burst release
• Implant integrity
• Goserelin diffusion
• Polymer hydration
• Degradation rate
• Local tissue response
• Dose duration
• Residual polymer after dosing
• Manufacturing reproducibility

Zoladex is generally described as a depot implant rather than a conventional microsphere product. That distinction matters because the implant geometry, polymer molecular weight, monomer ratio, porosity, drug loading, and compression or extrusion conditions can materially affect clinical performance.

How does the Zoladex polymer matrix control drug release?

The lactide-glycolide matrix controls goserelin exposure through a combination of diffusion and polymer degradation.

After implantation, water enters the polymer matrix. Goserelin diffuses through hydrated pathways while the polymer undergoes hydrolysis. The release profile is affected by the following variables:

Formulation variable	Commercial and technical effect
Lactide-to-glycolide ratio	Changes water uptake and degradation speed
Polymer molecular weight	Influences mechanical strength and release duration
End-group chemistry	Can alter polymer hydration and degradation
Drug loading	Affects implant size, burst release, and dose uniformity
Implant dimensions	Influences surface-area-to-volume ratio
Polymer crystallinity	Can change degradation and mechanical behavior
Residual solvent or moisture	Affects stability and release consistency
Compression or extrusion conditions	Affects density, porosity, and implant strength
Sterilization process	Can reduce polymer molecular weight or alter drug stability
Packaging moisture barrier	Protects polymer and active ingredient during storage

For a monthly 3.6 mg product, the formulation must sustain release for approximately four weeks. The 10.8 mg product must maintain pharmacologically relevant release for approximately three months. Dose proportionality cannot be assumed because the two strengths can differ in implant geometry, surface area, drug loading, polymer properties, and release kinetics.

What excipient characteristics are commercially important for Zoladex competitors?

The commercial objective is not simply to reproduce the polymer name. A competitor must reproduce the overall product performance.

Polymer grade

A suitable polymer must have a controlled lactide-to-glycolide ratio, narrow molecular-weight distribution, low residual monomer content, controlled water content, and consistent degradation behavior. Pharmaceutical-grade poly(lactic-co-glycolic acid), or PLGA, is available from specialist suppliers, but the relevant grade must be qualified for implant use rather than assumed suitable based on injectable or microsphere experience.

Drug-polymer compatibility

Goserelin is a potent peptide analogue. Compatibility work must address:

• Peptide adsorption to the polymer
• Chemical degradation during processing
• Aggregation or oligomerization
• Local pH changes caused by polymer hydrolysis
• Oxidation and deamidation
• Loss of potency during sterilization
• Release of acidic degradation products

Manufacturing reproducibility

The implant must meet tight specifications for:

• Goserelin content
• Content uniformity
• Dimensions
• Weight
• Mechanical strength
• In vitro release
• Sterility
• Endotoxin
• Degradation profile
• Applicator compatibility

Small changes in extrusion temperature, compression force, polymer moisture, or residence time can alter release behavior. This creates a meaningful manufacturing barrier for generic entrants.

Local tolerability

Because the implant is placed subcutaneously, the excipient system must be assessed for injection-site pain, inflammation, fibrosis, nodules, and delayed tissue response. The polymer degradation products may lower local pH, making biocompatibility and tissue histology important development considerations.

What formulation patents protect Zoladex?

Zoladex's original protection was directed primarily to goserelin, sustained-release delivery, implant formulations, and administration methods. The earliest composition and use patents are legacy rights in major markets and are generally beyond their original terms.

The commercial protection that remains relevant is more likely to arise from:

• Later formulation patents
• Manufacturing-process patents
• Applicator-device patents
• Packaging and stability patents
• Narrow method-of-use patents
• Patent rights covering particular polymer grades or release profiles
• Regulatory exclusivities associated with later indications

Patent scope must be assessed separately by jurisdiction. A patent covering a biodegradable implant or a GnRH agonist depot does not necessarily block a product using a different polymer grade, implant geometry, or manufacturing process.

Protection category	Relevance to Zoladex competition
Original goserelin compound patents	Primarily historical
Implant composition patents	Potentially relevant if later-filed claims remain active
Polymer and release-control claims	Important for complex-generic design-around analysis
Applicator-device claims	Can affect device substitution
Method-of-use claims	Relevant to prostate cancer, breast cancer, and endometriosis indications
Manufacturing claims	Can create practical barriers even after composition patents expire
Data exclusivity	Usually less important for an established product than patent and approval requirements

The FDA Orange Book should be reviewed for current listed patents associated with each Zoladex NDA. Patent expiry cannot be inferred solely from the original approval date because later patents, pediatric extensions, terminal disclaimers, patent-term adjustments, and regulatory exclusivity can change the effective blocking position.[3]

When does Zoladex lose exclusivity?

Zoladex's original active-ingredient and primary formulation protection has expired or is no longer the principal commercial barrier in major markets. The more important question is whether a competitor can obtain approval for an implant that is sufficiently equivalent to the reference product.

Zoladex was first approved in the United States in 1989 for the 3.6 mg implant. The 10.8 mg implant was subsequently approved for longer-interval dosing.[1,2] The product is therefore a mature reference drug with established clinical use and extensive post-market experience.

Current entry risk depends on:

1. Whether an active Orange Book patent remains listed.
2. Whether a generic applicant can file an abbreviated application for the implant.
3. Whether FDA requires clinical endpoint data or comparative pharmacokinetic data.
4. Whether the product is treated as a complex drug-device combination.
5. Whether the applicant can reproduce release performance and local tolerability.
6. Whether the reference product has an available or commercially usable comparator.
7. Whether the applicant receives approval for all reference indications.

What is the FDA regulatory status of Zoladex?

Zoladex is an FDA-approved goserelin acetate implant marketed by AstraZeneca. The product is used in hormone-sensitive conditions, including:

• Prostate cancer
• Breast cancer in appropriate premenopausal or perimenopausal patients
• Endometriosis
• Endometrial thinning before endometrial ablation in the 3.6 mg presentation

The implant is administered subcutaneously by a healthcare professional using a dedicated applicator. The drug-device presentation increases development complexity compared with a conventional injectable.

A prospective competitor may face several regulatory pathways:

Development route	Strategic implication
Abbreviated new drug application	Potentially available, but equivalence for a long-acting implant may be difficult
505(b)(2) application	Useful where formulation, device, or clinical bridging differs from the reference product
Full NDA	Highest cost and longest timeline, but permits greater formulation differentiation
Authorized generic	Rapid market entry with lower technical risk if commercial rights are available
Regional hybrid application	Relevant outside the United States where local rules recognize complex generics

A generic applicant should expect FDA scrutiny of in vitro release, implant characterization, peptide integrity, polymer degradation, sterility, applicator performance, and clinical safety. Conventional immediate-release bioequivalence methods are unlikely to capture the full risk profile of a three-month implant.

Are there Paragraph IV challenges to Zoladex?

Paragraph IV exposure is possible when an applicant files an ANDA asserting that listed patents are invalid, unenforceable, or not infringed. The practical value of a Paragraph IV strategy depends on whether active Orange Book patents cover the reference product at the time of filing.

For a mature product such as Zoladex, the primary risk is less likely to be the original compound patent. It is more likely to involve later patents covering:

• Release duration
• Polymer composition
• Implant structure
• Applicator configuration
• Manufacturing conditions
• Specific treatment regimens

A challenger may pursue a design-around strategy instead of directly contesting a formulation patent. For example, it may use a different polymer molecular-weight range or implant geometry while matching the reference product's release profile.

Patent litigation risk is highest when the applicant seeks a 180-day first-filer opportunity or when the reference sponsor has listed later formulation or device patents. Current litigation status must be confirmed through the FDA Orange Book, FDA approval databases, PACER, and relevant national patent registers.[3-5]

How strong is the Zoladex patent estate?

The legacy estate is commercially weaker than it was during the product's launch period because goserelin and the basic depot concept are mature technologies. The practical competitive moat remains moderate to strong in manufacturing and regulatory execution.

Estate component	Relative barrier
Active ingredient	Low for modern entry
Basic sustained-release concept	Low to moderate
Specific implant composition	Moderate
Three-month release performance	Moderate to high
Applicator and device integration	Moderate
Sterile implant manufacturing	High
Clinical experience and physician familiarity	Moderate
Supply reliability	Moderate
Regulatory comparability	High

The product's strongest protection is therefore a combination of know-how, process control, clinical history, and market access. These barriers can remain meaningful after core patents expire.

What commercial opportunities exist in Zoladex excipients?

Complex generic goserelin implants

A generic implant could compete on price in public procurement, oncology tenders, and markets where branded switching is limited by reimbursement pressure. The main opportunity is to reproduce the reference release profile without copying protected manufacturing steps.

The 10.8 mg product may be commercially attractive because quarterly dosing reduces administration burden and may improve persistence. It also has higher unit value than the monthly product, although the technical burden is greater.

Polymer supply and licensing

Specialty polymer manufacturers can supply:

• Implant-grade PLGA
• Controlled molecular-weight polymer
• Low-moisture polymer
• Custom lactide-glycolide ratios
• GMP documentation
• Extractables and leachables packages
• Regulatory support
• Scale-up and process-development services

A polymer supplier with demonstrated experience in peptide depots, sterile implants, or long-acting injectables has a stronger commercial position than a commodity PLGA supplier.

Differentiated depot formulations

A developer could pursue a 16-week or six-month goserelin depot, subject to clinical and regulatory requirements. Longer dosing intervals may reduce clinic visits and administration costs. However, a longer-duration formulation would likely require substantial clinical bridging and may encounter new formulation or method-of-use patents.

Potential differentiation includes:

• Six-month release
• Lower injection force
• Smaller implant
• Reduced initial burst
• Lower local inflammation
• Improved applicator ergonomics
• Room-temperature stability
• Reduced storage burden
• Preassembled administration systems

Regional licensing

Regional partners may have value in markets where AstraZeneca's distribution, pricing, or supply position is limited. Licensing structures could include:

• Territory-specific rights
• Supply of polymer or finished implants
• Technology-transfer agreements
• Co-development of a generic
• Authorized-generic arrangements
• Contract manufacturing
• Local packaging and device assembly

The highest-value licensing asset is a validated implant process with regulatory comparability data, not an unqualified polymer specification.

What manufacturing and intellectual-property barriers affect generic launch?

The principal barriers are sterile production, release testing, polymer control, and device integration.

A competitor must establish a reproducible process for combining goserelin with the polymer without damaging the peptide. It must also demonstrate that scale-up does not change implant density, residual solvent, degradation rate, or release kinetics.

Commercial launch risks include:

• Failure to match the full release curve
• Excessive initial drug release
• Inconsistent implant dimensions
• Applicator obstruction or incomplete delivery
• Sterility failures
• Polymer batch variability
• Limited availability of qualified polymer
• Patent claims covering process parameters
• Inability to secure a reference-product supply
• Physician reluctance to switch established patients

These issues make Zoladex more difficult to copy than a conventional goserelin injection. The product can be patent-expired while remaining technically challenging.

How does Zoladex compare with competing GnRH therapies?

Product class	Example	Administration	Excipient and device complexity	Competitive position
Biodegradable implant	Zoladex	Monthly or quarterly subcutaneous implant	High	Strong depot differentiation
Microsphere depot	Leuprolide products	Monthly to six-month injection	High	Broad competitive field
In situ depot	Some long-acting injectable products	Subcutaneous or intramuscular injection	Moderate to high	Potentially easier administration
Oral GnRH antagonist	Relugolix, elagolix	Daily oral dosing	Low formulation complexity, higher adherence burden	Avoids implant procedure
Injectable GnRH antagonist	Degarelix	Monthly injection	Moderate	Rapid suppression, no implant
Other GnRH agonists	Leuprolide, triptorelin	Depot injection	Moderate to high	Established alternatives

Zoladex's commercial advantages are long duration, established efficacy, and a small implant volume. Its disadvantages include insertion requirements, local-site reactions, device dependence, and competition from oral hormone therapies and newer injectable products.

What revenue exposure and launch scenarios are relevant?

Revenue exposure is concentrated in indications where long-term androgen deprivation or ovarian suppression is clinically established. A generic entrant could produce three commercial scenarios:

Scenario	Market effect
Single approved generic	Limited price erosion; procurement-driven substitution
Multiple approved generics	Rapid tender-price decline and greater hospital switching
Differentiated long-duration product	Premium or parity pricing if administration savings are demonstrated

The most vulnerable segment is price-sensitive institutional procurement. The most defensible segment is specialist use where physicians value established implant performance and predictable release.

A launch strategy should prioritize the 3.6 mg and 10.8 mg strengths together if manufacturing economics permit. Offering only one strength may limit formulary adoption and create supply disadvantages.

Key Takeaways

• Zoladex's principal excipient is a biodegradable lactide-glycolide copolymer that controls goserelin release.
• The formulation is a complex sterile implant, not a conventional injectable.
• Generic entry is constrained more by release-profile replication, polymer control, sterility, and applicator performance than by the expired core compound patent.
• The 10.8 mg, 12-week implant offers a potentially attractive commercial target because of its higher dose and reduced administration frequency.
• Specialty PLGA suppliers can capture value through qualified polymer grades, regulatory support, and process-development partnerships.
• The strongest lifecycle opportunities are longer-duration depots, improved applicators, lower local reactivity, and better storage stability.
• Current Orange Book listings and court records must determine whether any later formulation, process, device, or method-of-use patents remain relevant to a specific launch date.
• Competition comes from leuprolide and triptorelin depots, degarelix, oral GnRH antagonists, and other hormone-suppression products.

FAQs About Zoladex Excipients and Commercial Strategy

Is PLGA the same as the polymer used in Zoladex?

Lactide-glycolide copolymer is a form of PLGA, but commercial PLGA grades are not interchangeable. Molecular weight, monomer ratio, end-group chemistry, moisture, and residual solvent can change implant performance.

Can a generic manufacturer use a different excipient from Zoladex?

A different polymer or polymer grade may be possible, but the applicant must demonstrate pharmaceutical equivalence, bioequivalence or appropriate clinical bridging, equivalent release performance, safety, and device compatibility under the applicable regulatory pathway.

Does Zoladex contain preservatives?

Zoladex is a solid implant rather than a multidose liquid injection. The FDA labeling identifies the biodegradable polymer matrix as the principal formulation excipient and does not describe the product as relying on a conventional preservative system.[1,2]

Is a Zoladex competitor a biologic or biosimilar product?

No. Goserelin is a synthetic peptide analogue regulated as a drug. A competing product would generally be evaluated through a generic, hybrid, 505(b)(2), or full NDA pathway rather than the biosimilar pathway.

Can a six-month goserelin implant directly substitute for Zoladex?

No. A six-month product would require its own regulatory approval, dosing instructions, safety evidence, release characterization, and potentially separate patent and method-of-use analysis.

References

1. U.S. Food and Drug Administration. (2023). Zoladex 3.6 mg prescribing information. AstraZeneca Pharmaceuticals LP.

2. U.S. Food and Drug Administration. (2023). Zoladex 10.8 mg prescribing information. AstraZeneca Pharmaceuticals LP.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/

5. U.S. Patent and Trademark Office. (2024). Patent Center. https://patentcenter.uspto.gov/